---
title: "Adicet Bio, Inc. (ACET.US)"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/ACET.US.md"
symbol: "ACET.US"
name: "Adicet Bio, Inc."
industry: "Biotechnology"
datetime: "2026-03-07T08:35:10.024Z"
locales:
  - [en](https://longbridge.com/en/quote/ACET.US.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/ACET.US.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/ACET.US.md)
---

> Supported Languages: [简体中文](https://longbridge.com/zh-CN/quote/ACET.US.md) | [繁體中文](https://longbridge.com/zh-HK/quote/ACET.US.md)


# Adicet Bio, Inc. (ACET.US)

## Company Overview

Adicet Bio, Inc., a clinical stage biotechnology company, discovers and develops allogeneic gamma delta T cell therapies for autoimmune diseases and cancer in the United States. It offers gamma delta T cells engineered with chimeric antigen receptors (CARs) to facilitate durable activity in patients. The company’s lead product candidate is ADI-001, an allogeneic gamma delta T cell therapy expressing a CAR targeting CD20, which is in Phase I clinical trial for the potential treatment of autoimmune diseases and relapsed/refractory B-cell non-hodgkin’s lymphoma. It also develops ADI-270, an armored gamma delta CAR T cell product candidate to treat multiple CD70+ solid tumor and hematological malignancies indications, with renal cell carcinoma.

| Item | Detail |
|------|--------|
| Industry | Biotechnology |
| Exchange | US Market |
| Website | [www.adicetbio.com](https://www.adicetbio.com) |

## Key Drivers
> *AI-analyzed key factors driving this stock's performance*


## Longbridge Financial Score™: 
> *Longbridge Financial Score™ — Proprietary multi-factor rating model by Longbridge*
> Updated: 1970-01-01T00:00:00.000Z

**Overall:  (0.00)**

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | -0.61 | 154 | - | - | - |
| PB | 0.64 | 53 | 0.73 | 0.47 | 0.34 |
| Dividend Yield | 0.00% | - | - | - | - |

## Institutional View

### Analyst Rating Distribution

> As of 2026-01-23T05:00:00.000Z

Total Analysts: **7**

| Rating | Count | Percentage |
|--------|-------|-----------| 
| Buy | 7 | 100% |

### Target Price Forecast

| Metric | Price |
|--------|-------|
| Current Price | 7.29 |
| Highest Target | 128.00 |
| Lowest Target | 18.00 |

## References

- [Company Overview — Profile, executives, shareholders, business breakdown](https://longbridge.com/en/quote/ACET.US/overview.md)
- [Financial Reports — Income, balance sheet, cash flow, dividends](https://longbridge.com/en/quote/ACET.US/norm.md)
- [Related News](https://longbridge.com/en/quote/ACET.US/news.md)
- [Filings — Company announcements and regulatory filings](https://longbridge.com/en/quote/ACET.US/filings.md)

---

> **Disclaimer: This article is for reference only and does not constitute any investment advice.**